Generic filters
Filter by content type
Taxonomy terms

VCNX – Vaccinex Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 0

Company Profile

Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate, pepinemab (VX15/2503), is a humanized monoclonal antibody that binds and blocks the signaling activity of semaphorin 4D (SEMA4D). It is focused on the development of pepinemab for the treatment of certain cancer indications, in particular, head and neck squamous cell carcinoma (HNSCC) as well as neurodegenerative diseases, including Huntington’s disease (HD), and Alzheimer’s disease, (AD). The Company has discovered VX5 using its ActivMAb antibody discovery platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of multiple sclerosis (MS) and for other autoimmune disorders.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan